Field Safety Notices: 3 to 7 November 2025
List of Field Safety Notices from 3 to 7 November 2025.
-
-
Class 3 Medicines Recall: Sun Pharmaceutical Industries Limited, Atorvastatin 20mg and 80mg Film-coated Tablets, EL(25)A/48
Sun Pharma UK Limited are recalling the batches of tablets specified in the table as a precautionary measure due to failing dissolution test results reported during ongoing stability studies.
-
MHRA-led study reveals major inconsistencies in global microbiome research
International collaboration establishes new quality standards to improve reliability of gut health studies – improving accuracy to provide better diagnosis and treatment.
-
Class 3 Medicines Recall: Zambon SpA, Emylif 50mg orodispersible film, EL(25)A/47
Zambon SpA is recalling an affected batch as a precautionary measure due to out of specification results for unknown impurities during ongoing stability testing.
-
Dr Alison Cave: Pharmacists are on the frontline of medicines safety – and your reports make all the difference
As part of #MedSafetyWeek, the MHRA’s Chief Safety Officer reflects in The Pharmacist on the vital role pharmacists play in keeping medicines and medical devices safe.
-
MHRA approves Siiltibcy as a diagnostic aid for Mycobacterium tuberculosis infection, including disease
The Medicines and Healthcare products Regulatory Agency (MHRA) has approved Siiltibcy
-
RegulatoryConnect
The Medicines and Healthcare Regulatory Agency have launched RegulatoryConnect, a service that provides the capability to track applications and view live authorisation details.
-
Decision: Advertising Investigations: October 2025
Decisions made by the MHRA following investigations into complaints about advertising for licensed medicines.
-
Field Safety Notices: 27 to 31 October 2025
List of Field Safety Notices from 27 to 31 October 2025.
-
MHRA appoints first Chief Medical and Scientific Officer
Professor Jacob George has been appointed as the first Chief Medical and Scientific Officer for the Medicines and Healthcare products Regulatory Agency (MHRA).
-
Isotretinoin: an expert review of suspected psychiatric and sexual side effects
The review of the safety of isotretinoin has concluded.
-
Professor Henrietta Hughes: Putting Patient Safety at the Heart of Regulatory Innovation
Professor Henrietta Hughes reflects on how MHRA strategy must prioritise patient safety via listening to lived experiences, fostering collaboration & innovation.